
Opinion|Videos|December 21, 2023
Overview of the Systemic Treatment Options for Advanced RCC
Author(s)Thomas E. Hutson, DO, PharmD, Kacie Ellis, RN
Kidney cancer, which once had few treatment options, now has multiple oral targeted therapies leading to improved survival; immunotherapy combinations further increased clinical benefit over previous options, providing clinicians several approved regimens from which to choose the optimal therapy for each patient.
Advertisement
Episodes in this series

Advertisement
Related to this article

The CHMP recommended belzutifan plus lenvatinib for advanced clear cell RCC after anti–PD-(L)1 therapy, based on phase 3 LITESPARK-011 data.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how subsequent therapy and durable responses may have shaped overall survival results in LITESPARK-011.

Daniel Y.C. Heng, MD, MPH, FRCPC, explained how he manages anemia, hypoxia, and cardiac toxicity with belzutifan plus lenvatinib for renal cell carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
Rethinking HCC Surveillance and Treatment Amid a Shifting Risk Landscape
2
Sequencing B7-H3 and SEZ6 ADCs With DLL3 Bispecifics in SCLC
3
Efti Plus Pembrolizumab and RT Yields 81% 12-Month DFS in Soft Tissue Sarcoma
4
Testosterone Therapy Shows No Added Progression Risk in Active Surveillance PCa
5


